Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

Proposal for a revised classification of systemic mastocytosis

(2010) A. Pardanani et al.   BLOOD

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults

(2010) A. Pardanani et al.   BLOOD

Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit

(2010) A. Gerbaulet et al.   BLOOD

Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis

(2010) K. J. Aichberger et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V

(2010) Alexandra Böhm et al.   EXPERIMENTAL HEMATOLOGY

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

(2009) Ken H. Lim et al.   AMERICAN JOURNAL OF HEMATOLOGY

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

(2009) K.-H. Lim et al.   BLOOD

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

(2009) A. Pardanani et al.   BLOOD

Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology

(2009) W. R. Sperr et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients

(2009) Luis Escribano et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations

(2009) Christine Bodemer et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Variable presence ofKITD816Vin clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)

(2009) Karl Sotlar et al.   JOURNAL OF PATHOLOGY

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

(2009) Arturo Vega-Ruiz et al.   LEUKEMIA RESEARCH

Pediatric-onset mastocytosis: A long term clinical follow-up and correlation with bone marrow histopathology

(2009) Ashraf Uzzaman et al.   PEDIATRIC BLOOD & CANCER

Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

Dasatinib therapy for systemic mastocytosis: four cases

(2008) Duncan Purtill et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Advanced mast cell disease: an Italian Hematological Multicenter experience

(2008) Livio Pagano et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V

(2008) Celalettin Ustun et al.   LEUKEMIA RESEARCH